Download Sample
Schedule a Meeting
Table of Content
NA : +1 804 441 9344
sales@towardshealthcare.com
August 2025
The global plasma fractionation market size was estimated at US$ 32.75 billion in 2023 and is projected to grow to US$ 72.86 billion by 2034, rising at a compound annual growth rate (CAGR) of 7.54% from 2024 to 2034.
Plasma fractionation is a complex process to separate blood plasma into individual components, predominantly protein which includes clotting factors, albumin, immunoglobulins and fibrinogens, other components are enzymes and antibodies with phenomenal therapeutical values. Plasma fractionation is widely used in pharmaceutical research to treat chronic diseases. The worldwide rising demand for plasma derivatives due to increased immune disease, coagulation disorders and genetic defects is fuelling the market growth.
The chromatography-based method for plasma separation rapidly gaining popularity as offers gradual improvement, improves purity and enables the production of new classes of therapeutics. Plasma contains over 120 varieties of protein. When these proteins are extracted pure and concentrated, they can create life-saving therapeutics which are crucial for the treatment of several diseases such as immune deficiencies and bleeding disorders.
Even today, modern plasma fractionation technology relies on the original, ethanol-based protocol which is mostly used to isolate albumin. To produce novel plasma products which can be used to treat protein deficiencies, it is essential to implement chromatographic techniques. This precise technique has the ability to capture even trace protein. With the help of ion-exchange chromatography (IEC), proteins at their original pH and ionic strength, even fragile proteins (such as coagulation factors, anticoagulants, and protease inhibitors) are preserved and isolated.
A study published in the journal Science Translational Medicine mentions a pattern developing with certain blood plasma protein levels that can lead to the development of sepsis in patients. A team of medical researchers analysed the plasma profiles of hundreds of ICU patients who had developed sepsis. When the body shows dysregulated response to infection, it the known as sepsis condition. It is considered a life-threatening condition as it leads to multiple organ failure. Every year in the United Kingdom approximately 50,000 deaths are noted due to sepsis.
The researchers drew out plasma samples from 16,000 patients and measured protein levels for plasma proteome using tandem mass spectrometry and liquid chromatography on 2,600 samples. The results provide a general profile which is used to identify patients at risk.
The increasing incidence of chronic disease is increasing the demand for plasma-derived treatment options. At the same time, they are also being used for the treatment of autoimmune and neurological disorders. Moreover, the presence of limited alternatives is increasing their use. Thus, to deal with this growing demand, the use as well as the demand for plasma fractionation facilities increases. At the same time, the growing developments in plasma-derived therapies also contribute to the same. Thus, this promotes the plasma fractionation market growth.
In June 2025, to expand the plasma fractionation product storage facilities across Andong, 12 billion won will be invested by SK Plasma. To establish freezing facilities and refrigeration facilities near its existing Andong fractionation center for storing raw plasma and finished pharmaceuticals, respectively, this investment will be utilized.
North America dominated the global plasma fractionation market in 2023. The unites states is the largest supplier of Plasma Fractionation in the world. As US has a policy of paid donors while other countries obtain plasma from volunteers and unpaid donors. Therefore, the rate of plasma collection is less in other countries. Canadian Blood Service uses raw plasma to produce a category of drugs such as plasma protein and related products. Additionally, the three largest plasma product companies in the U.S. – CSL Plasma, Grifols and BioLife, collect over 75% of total plasma for fractionation in the States. That are about 54% more plasma donation centres in the US than there were four years back. With the rising demand for plasma on every basis of 6,500 units, there needs to be a consistent donation rate.
In Canada, 52% of people or their family members require blood or blood products at some point in their lifetime. Canadian Blood Services (CBS) is an NGO that collects and recruits blood, plasma, and platelets at 36 collection sites and more than 14,000 donor clinics annually.
Europe is anticipated to register the fastest growth in the haptic devices market during the forecast period of 2024 to 2034. The growth in this region depends upon the European Union's attainment of open strategic autonomy and improved competitiveness. European Union institutes, governments and businesses are working towards a better understanding of potential vulnerabilities and opportunities to modify policies to ensure a resilient supply of plasma and plasma-derived medicinal products. This action will provide a better solution for the EU and national level to achieve recognition.
The National Health Service (NHS) aims to collect 300,000 liters of plasma annually. In July 2023, Octapharma was appointed as the sole fractionator for the UK’s Plasma for Medicines Program. The program was launched to reduce the reliance on external plasma sources and ensure a stable and affordable supply of these products in the UK.
About 2 million people donate blood annually in Germany, accounting for 2-3% of the total population. In March 2023, CSL opened a new $470 million plasma fractionation facility in Marburg, Germany. The state-of-the-art facility was opened to transform human plasma into life-saving medicines.
Asia-Pacific is expected to grow at a considerable rate in the plasma fractionation market in the upcoming period. Numerous government and private organizations launch initiatives and conduct workshops to create awareness about blood and plasma donations among the general public. The rising adoption of advanced technologies to streamline the fractionation process boosts the market. The increasing prevalence of blood-related disorders and the availability of a suitable manufacturing infrastructure drive the market.
In India, 14.6 million blood are required annually, and there is a shortage of approximately 1 million. Hence, the Indian government promotes blood donation through “Raktdan Amrit Mahotsav”. The E-Rakt Kosh portal is a national repository of blood donors.
Latin America is expected to grow significantly in the plasma fractionation market during the forecast period. The healthcare sector in Latin America is advancing. They are developing as well as adapting to various advanced treatment options to tackle the growing rates of genetic disorders. This, in turn, is increasing the research and development of plasma-derived therapies for their treatment, which in turn is increasing the demand for plasma fractionation facilities. Thus, the adoption of these facilities and the development of the therapies are being supported by the government initiatives and investments. Thus, this is promoting the market growth.
By type, Immune Globulin dominated the plasma fractionation market in 2023. The growth of this segment is noticed by plasma-derived immunoglobulins are provided with a new narrative in the healthcare industry for a wide range of autoimmune inflammatory diseases. Immune globulin is needed for a patient who cannot make enough antibodies. This provides externally sourced antibodies for recovery.
The Coagulation Factor segment is expected to grow significantly in the plasma fractionation market during the forecast period of 2024 to 2034. The expansion of this segment is observed due to its ability to stop bleeding when injured. It includes a system of proteins that controls the conversion of soluble plasma fibrinogen to fibrin, an insoluble polymer that forms a gel network to stop bleeding.
By application, the hospital segment stood dominant in the plasma fractionation market in 2023. The dominance is observed due to the wide utilization of plasma at hospitals for emergency cases to boost blood volume in trauma patients, prevent shock and help with blood clotting. Healthcare providers supply various plasma-derived medicinal products to hospitals and other healthcare facilities for the treatment of patients with immune deficiency disorders, immunodeficiency virus, hepatitis virus and many more.
The retail pharmacy segment is anticipated to grow with the highest CAGR in the plasma fractionation market during the studied years. Pharmaceutical companies extract components from raw human plasma using centrifugation, depth filtration and chromatographic methods. The manufacturing process is carried out to produce effective and safe drugs.
In January 2025, financial results were released by Takeda Pharmaceutical Company Limited, which were 3.5 trillion, with an increase of 9.8% year-on-year. Revenue growth was reported. The core operating profit showed JPY 1 trillion, indicating a rise of 16.3% year-on-year and JPY 835 billion, reflecting 90.8% growth, which was reported for operating cash flow. Moreover, significant growth in growth & launch products was observed with 47% of total revenue. There was a global rise in the demand for vaccines, Kudanga with around 10 million doses, while plasma-derived therapies such as albumin and immunoglobulin showed a growth of 2.2% and 11.9%, respectively.
In March 2025, the Biotest Group released its financial results, which reported € 726.2 million in sales, indicating a 6.1 % growth in sales. The sale increased from € 34.9 million to € 62.1 million for their new intravenous immunoglobulin Yimmugo®. Moreover, adjusted EBIT was observed to be € 64.5 million in the past financial year, where € 65 to 85 million is its forecast amount. Additionally, € 46.5 million was noted to be the earnings before taxes (EBT). Similarly, the EAT amounted to € 26.4 million for the 2024 financial year.
By Type
By Application
By Region
August 2025
August 2025
August 2025
August 2025